We evaluated mean platelet volume (MPV; an indicator of vascular risk) and platelet distribution width in patients with stable chronic obstructive pulmonary disease (COPD; n = 85). We also included a control group of 34 smokers without airflow limitation. Mean platelet volume was significantly higher in patients with COPD (10.69 ± 1.0 vs 9.96 ± 1.10 fL, P < .001) than in the smoker controls. White blood cell (WBC) count was also significantly higher in patients with COPD than in the smoker controls (10 642 ± 1247 vs 7136 ± 1887/μL, P < .001). There was a correlation between MPV and WBC in patients with COPD, especially in those at stage III (r = .530, P = .004) and IV (r = .389, P = .023). Mean platelet volume did not correlate with any indices of COPD severity. In patients with COPD, MPV and WBC levels are higher than those of smokers with normal pulmonary function and are significantly correlated. Whether these effects relate to vascular risk in patients with COPD remain to be established.
CoultasDBMapelDGagnonRLydickE. The health impact of undiagnosed airflow obstruction in a national sample of United States adults. Am J Respir Crit Care Med. 2001;164(3):372–377.
2.
MurrayCJLopezAD. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study. Lancet. 1997;349(9064):1498–1504.
MichaudCMMurrayCJBloomBR. Burden of disease-implications for future research. JAMA. 2001;285(5):535–539.
5.
SullivanSDRamseySDLeeTA.The economic burden of COPD. Chest. 2000;117(2 suppl):5S–9S.
6.
GeitonaMHatzikouMSteiropoulosPAlexopoulosECBourosD. The cost of COPD exacerbations: a university hospital-based study in Greece. Respir Med. 2011;105(3):402–409.
7.
SteiropoulosPPapanasNNenaEBourosD. Indacaterol: a new long-acting β2-agonist in the management of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2012;13(7):1015–1029.
8.
SteiropoulosPTzouvelekisABourosD. Formoterol in the management of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008;3(2):205–215.
9.
AgustiAG. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(4):367–370.
10.
FimognariFLScarlataSConteMEIncalziRA. Mechanisms of atherothrombosis in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008;3(1):89–96.
11.
FimognariFLScarlataSAntonelli-IncalziR. Why are people with “poor lung function” at increased atherothrombotic risk? A critical review with potential therapeutic indications. Curr Vasc Pharmacol. 2010;8(4):573–586.
12.
TsiaraSElisafMJagroopIAMikhailidisDP. Platelets as predictors of vascular risk: is there a practical index of platelet activity?Clin Appl Thromb Hemost. 2003;9(3):177–190.
13.
JagroopIAClatworthyILewinJMikhailidisDP. Shape change in human platelets: measurement with a channelyzer and visualisation by electron microscopy. Platelets. 2000;11(1):28–32.
14.
ParkYSchoeneNHarrisW. Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets. 2002;13(5-6):301–306.
15.
VagdatliEGounariELazaridouEKatsibourliaETsikopoulouFLabrianouI. Platelet distribution width: a simple, practical and specific marker of activation of coagulation. Hippokratia. 2010;14(1):28–32.
16.
GasparyanAYAyvazyanLMikhailidisDPKitasGD. Mean platelet volume: a link between thrombosis and inflammation?Curr Pharm Des. 2011;17(1):47–58.
17.
VizioliLMuscariSMuscariA. The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int J Clin Pract. 2009;63(10):1509–1515.
18.
PapanasNSymeonidisGMaltezosE. Mean platelet volume in patients with type 2 diabetes mellitus. Platelets. 2004;15(8):475–478.
19.
HekimsoyZPayzinBOrnekTKandoğanG. Mean platelet volume in type 2 diabetic patients. J Diabetes Complications. 2004;18(3):173–176.
20.
PapanasNMavridisGKaravageliESymeonidisGMaltezosE. Peripheral neuropathy is associated with increased mean platelet volume in type 2 diabetic patients. Platelets. 2005;16(8):498–499.
21.
BiljakVRPancirovDCepelakIPopović-GrleSStjepanovićGGrubišićTŽ. Platelet count, mean platelet volume and smoking status in stable chronic obstructive pulmonary disease. Platelets. 2011;22(6):466–470.
22.
CuiHLiuLWeiZ. Clinical value of mean platelet volume for impaired cardiopulmonary function in very old male patients with chronic obstructive pulmonary disease. Arch Gerontol Geriatr. 2012;54(2):e109–e112.
23.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011;34(suppl 1):S62–S69.
24.
KatsikiNPapanasNMikhailidisDPFonsecaVA. Glycated hemoglobin A(1c) (HbA1c) and diabetes: a new era?Curr Med Res Opin. 2011;27(suppl 3):7–11.
25.
ChobanianAVBakrisGLBlackHR. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206–1252.
26.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–3421.
27.
BlackburnHKeysASimonsonERautaharjuPPunsarS.The electrocardiogram in population studies. A classification system. Circulation. 1960;21:1160–1175.
28.
DicksteinKCohen-SolalAFilippatosG. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008;10(10):933–989.
29.
O’MalleyTLudlamCAFoxKAEltonRA. Measurement of platelet volume using a variety of different anticoagulant and antiplatelet mixtures. Blood Coagul Fibrinolysis. 1996;7(4):431–436.
30.
BansalRGuptaHLGoelAYadavM. Association of increased platelet volume in patients of chronic obstructive pulmonary disease: clinical implications. J Indian Acad Clin Med. 2002;3(2):169–172.
31.
OnderITopcuSDökmetasHSTürkayCSeyfikliZ. Platelet aggregation size and volume in chronic obstructive pulmonary disease. Mater Med Pol. 1997;29(1-4):11–13.
32.
UlasliSSOzyurekBAYilmazEBUlubayG. Mean platelet volume as an inflammatory marker in acute exacerbation of chronic obstructive pulmonary disease. Pol Arch Med Wewn. 2012;122(6):284–290.
33.
BarnesPJCelliBR.Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165–1185.
34.
NenaEPapanasNSteiropoulosP. Mean platelet volume and platelet distribution width in non-diabetic subjects with obstructive sleep apnoea syndrome: new indices of severity?Platelets. 2012;23(6):447–454.
35.
HuttonRAMikhailidisDPBernsteinRMJeremyJYHughesGRDandonaP. Assessment of platelet function in patients with Raynaud’s syndrome. J Clin Pathol. 1984;37(2):182–187.
36.
JagroopAMikhailidisDP. Platelet cholesterol: from man to seal [published online June 21, 2012]. Platelets. 2012.
37.
PapanasNMaltezosE. Cilostazol in diabetic neuropathy: premature farewell or new beginning?Angiology. 2011;62(8):605–608.
38.
MuratSNDuranMKalayN. Relation between mean platelet volume and severity of atherosclerosis in patients with acute coronary syndromes [published online February 14, 2012]. Angiology. 2012.
39.
YarliogluesMArdicIDogduO. The acute effects of passive smoking on mean platelet volume in healthy volunteers. Angiology. 2012;63(5):353–357.
40.
López-CuencaAATello-MontoliuARoldánVPérez-BerbelPValdésMMarínF. Prognostic value of mean platelet volume in patients with non-ST-elevation acute coronary syndrome. Angiology. 2012;63(4):241–244.
41.
OzkanBUysalOKDuranM. Relationship between mean platelet volume and atherosclerosis in young patients with st elevation myocardial infarction [published online June 4, 2012]. Angiology. 2012.
